ES2185691T3 - Inhibicion de la migracion y proliferacion de celulas musculares lisas con compuestos de hidroxicarbazol. - Google Patents

Inhibicion de la migracion y proliferacion de celulas musculares lisas con compuestos de hidroxicarbazol.

Info

Publication number
ES2185691T3
ES2185691T3 ES95902689T ES95902689T ES2185691T3 ES 2185691 T3 ES2185691 T3 ES 2185691T3 ES 95902689 T ES95902689 T ES 95902689T ES 95902689 T ES95902689 T ES 95902689T ES 2185691 T3 ES2185691 T3 ES 2185691T3
Authority
ES
Spain
Prior art keywords
compounds
proliferation
migration
smooth muscle
muscle cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95902689T
Other languages
English (en)
Inventor
Tian-Li Yue
Eliot H Ohlstein
Giora Z Feuerstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics Corp
Original Assignee
Boehringer Mannheim Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharmaceuticals Corp filed Critical Boehringer Mannheim Pharmaceuticals Corp
Application granted granted Critical
Publication of ES2185691T3 publication Critical patent/ES2185691T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN USO MEDICO NUEVO PARA LOS COMPUESTOS DE HIDROXICARBAZOLA DE LA FORMULA (I), PREFERIBLEMENTE LOS METABOLITOS HIDROXILADOS DE 1-(CARBAZOL-4-ILOXI-3-[[2-(OMETOXIFENOXI)ETIL]AMINO]-2-PROPANOL) (CARVEDILOL), PARA INHIBIR LA MIGRACION Y PROLIFERACION DE LAS CELULAS DEL MUSCULO LISO. EN PARTICULAR, LA PRESENTE INVENCION PROPORCIONA UN NUEVO USO PARA LOS COMPUESTOS DE HIDROXICARBAZOLA DE LA FORMULA (I) PARA PREVENCION DE LA RESTENOSIS POSTERIOR A LA ANGIOPLASTIA CORONARIA TRANSLUMINAL PERCUTANEA (PTCA), SUPRESION DE LA PROGRESION DE LA HIPERTROFIA VASCULAR ASOCIADA CON LA HIPERTENSION, Y LA PREVENCION DEL DESARROLLO DE LA ATEROESCLEROSIS. EN LA FORMULA (I), R{SUB,1}-R{SUB,9} SON INDEPENDIENTEMENTE -H O -OH, CON LA CONDICION QUE AL MENOS UNO DE R{SUB,1}-R{SUB,9} SEA OH.
ES95902689T 1993-11-24 1994-11-22 Inhibicion de la migracion y proliferacion de celulas musculares lisas con compuestos de hidroxicarbazol. Expired - Lifetime ES2185691T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/157,588 US5393772A (en) 1993-11-24 1993-11-24 Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation

Publications (1)

Publication Number Publication Date
ES2185691T3 true ES2185691T3 (es) 2003-05-01

Family

ID=22564393

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95902689T Expired - Lifetime ES2185691T3 (es) 1993-11-24 1994-11-22 Inhibicion de la migracion y proliferacion de celulas musculares lisas con compuestos de hidroxicarbazol.

Country Status (12)

Country Link
US (1) US5393772A (es)
EP (1) EP0741567B1 (es)
JP (1) JPH09505809A (es)
KR (1) KR100386229B1 (es)
CN (1) CN1102388C (es)
AT (1) ATE226072T1 (es)
AU (1) AU686706B2 (es)
CA (1) CA2176377A1 (es)
DE (1) DE69431568T2 (es)
ES (1) ES2185691T3 (es)
WO (1) WO1995014384A1 (es)
ZA (1) ZA949246B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1996040098A2 (en) 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
ZA977565B (en) * 1996-08-23 1999-02-17 Boehringer Mannheim Pharm Corp Method for inhibiting the expression of fas
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
AU765934B2 (en) * 1996-10-09 2003-10-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership No. 1 Method for inhibiting stress-activated protein kinases
IL129326A0 (en) 1996-10-09 2000-02-17 Boehringer Mannheim Pharm Corp Method for inhibiting stress-activated protein kinases
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
DE19830472B4 (de) * 1998-07-08 2013-06-27 Robert Bosch Gmbh Externe Komponente für ein Mikroprozessorsystem und Betriebsverfahren
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
WO2002026139A1 (en) * 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
PL370412A1 (en) * 2001-09-28 2005-05-30 F.Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
BR0312102A (pt) * 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
CA2492084A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
US10281374B2 (en) * 2015-11-04 2019-05-07 Diagnostic Biosystems Method of pretreatment of biological samples for an analyte-staining assay method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation

Also Published As

Publication number Publication date
EP0741567A4 (es) 1996-12-04
KR100386229B1 (ko) 2003-08-21
CN1135161A (zh) 1996-11-06
AU1186795A (en) 1995-06-13
CN1102388C (zh) 2003-03-05
DE69431568T2 (de) 2003-06-26
CA2176377A1 (en) 1995-06-01
ATE226072T1 (de) 2002-11-15
DE69431568D1 (de) 2002-11-21
ZA949246B (en) 1995-07-04
US5393772A (en) 1995-02-28
JPH09505809A (ja) 1997-06-10
AU686706B2 (en) 1998-02-12
EP0741567B1 (en) 2002-10-16
EP0741567A1 (en) 1996-11-13
WO1995014384A1 (en) 1995-06-01

Similar Documents

Publication Publication Date Title
EP0741567A4 (es)
AU674477B2 (en) Heterocyclic-cyclic amine derivatives
IL126339A0 (en) Taxol derivatives
AU7305194A (en) Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
DE69831937D1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
AU6783294A (en) Novel deoxygalactonojirimycin derivatives
TW325458B (en) Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
ZA9610315B (en) Naphthyl-substituted benzimidazole derivates as anti-coagulants
AR038433A2 (es) Derivados 2-alquil-2-desoxo de parahercuamida y marcfortina
AU2959995A (en) Stereochemical wortmannin derivatives
NO996578L (no) Urokinase-inhibitorer
BR9916567A (pt) Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares
ZA947970B (en) Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
DK1076663T3 (da) Funktionaliserede alkyl- og alkenylsidekædederivater af glycinamider som farnesyltransferaseinhibitorer
DK0687260T3 (da) Fremgangsmåde til fremstillingen af 9-desoxotaxaner
PT1189923E (pt) Derivados aromaticos e heterociclicos de fitosterois e/ ou fitostanois para utilizacao no tratamento ou prevencao de doenca cardiovascular
DK0766699T3 (da) Esterificerede polyanioniske cyclodextriner som inhibitorer af proliferation af glatte muskelceller
JO2065B1 (en) Tri-azin compounds
GR1002598B (el) Παραγωγα επι-επιβατιδινης.
DE69405760D1 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
NO994902L (no) Forebygging av brystkreft ved selektive östrogenreseptormodulatorer
ES2184885T3 (es) Derivados aza-antraciclinona.
ATE63309T1 (de) 2,3-dihydro-2-oxo-3-benzofuranylessigs|urederivate und diese enthaltende arzneimittel.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
IT1266584B1 (it) Composti eterociclici ad attivita' cardiovascolare